Impact of circulating vitamin D binding protein levels on the association between 25-hydroxyvitamin d and pancreatic cancer risk: A nested case-control study

Cancer Research

Volumn 72, Issue 5, 2012, Pages 1190-1198

  Weinstein, Stephanie J ^a   Stolzenberg Solomon, Rachael Z ^a   Kopp, William ^b   Rager, Helen ^b   Virtamo, Jarmo ^c   Albanes, Demetrius ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA TOCOPHEROL; BETA CAROTENE; CHOLESTEROL; RETINOL; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; UPREGULATION;

AGED; CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RISK FACTORS; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84857736678     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2950     Document Type: Article

References (35)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. IOM (Institute of Medicine). Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press, 2011.
3. Stolzenberg-Solomon RZ, Vieth R, Azad A, Pietinen P, Taylor PR, Virtamo J, et al. A prospective nested case-control study of vitamin D status and pancreatic cancer risk in male smokers. Cancer Res 2006;66:10213-9. (Pubitemid 44672077)
4. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, Qi D, Patel AV, Helzlsouer KJ, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010;172:81-93.
5. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372:33-42. (Pubitemid 44286753)
6. Cooke NE, Haddad JG. Vitamin D binding protein. In:Feldman D, Glorieux FH, Pike JW, editors. Vitamin D. San Diego, CA: Academic Press; 1997. p.87-101.
7. Bikle DD, Gee E. Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 1989;124:649-54. (Pubitemid 19057050)
8. The ATBC Cancer Prevention Study Group. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994;4:1-10.
9. Korhonen P, Malila N, Pukkala E, Teppo L, Albanes D, Virtamo J. The Finnish Cancer Registry as follow-up source of a large trial cohort-accuracy and delay. Acta Oncol 2002;41:381-8.
10. Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ, et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Prev 2000;9:403-12. (Pubitemid 30265784)
11. Gallicchio L, Helzlsouer KJ, Chow WH, Freedman DM, Hankinson SE, Hartge P, et al. Circulating 25-hydroxyvitamin D and the risk of rarer cancers: design and methods of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010;172:10-20.
12. Al-oanzi ZH, Tuck SP, Raj N, Harrop JS, Summers GD, Cook DB, et al. Assessment of vitamin D status in male osteoporosis. Clin Chem 2006;52:248-54. (Pubitemid 43185486)
13. Bouillon R, Van Assche FA, Van Baelen H, Heyns W, De Moor P. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D3. Significance of the free 1,25-dihydroxyvitamin D3 concentration. J Clin Invest 1981;67:589-96. (Pubitemid 11142347)
14. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986;63:954-9. (Pubitemid 16004301)
15. Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev 1995;4:655-9.
16. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 1996;5:121-6.
17. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, et al. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998;7:385-90. (Pubitemid 28354126)
18. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res 2009;69:1439-47.
19. Gomme PT, Bertolini J. Therapeutic potential of vitamin D-binding protein. Trends Biotechnol 2004;22:340-5. (Pubitemid 38887542)
20. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000;11:320-7.
21. Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response to injury. Clin Chem 2006;52:1247-53. (Pubitemid 43956013)
22. Rejnmark L, Lauridsen AL, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L. Diurnal rhythm of plasma 1,25-dihydroxyvitamin D and vitamin D-binding protein in postmenopausal women: relationship to plasma parathyroid hormone and calcium and phosphate metabolism. Eur J Endocrinol 2002;146:635-42. (Pubitemid 34552496)
23. Chun RF, Adams JS, Hewison M. Back to the future: a new look at 'old' vitamin D. J Endocrinol 2008;198:261-9.
24. Chishimba L, Thickett DR, Stockley RA, Wood AM. The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax 2010;65:456-62.
25. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40. (Pubitemid 36151056)
26. Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010;5:e13428
27. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, et al. Vitamin D binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011;26:1609-16.
28. Willnow TE, Nykjaer A. Cellular uptake of steroid carrier proteins-mechanisms and implications. Mol Cell Endocrinol 2010;316:93-102.
29. Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A. Vitamin D and cancer. J Steroid Biochem Mol Biol 2006;102:156-62. (Pubitemid 44781185)
30. Fleet JC. Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med 2008;29:388-96.
31. IARC. Vitamin D and cancer. Lyon, France: International Agency for Research on Cancer; 2009.
32. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995;53:579-82.
33. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004;15:255-65. (Pubitemid 38988034)
34. Hofmann JN, Yu K, Horst RL, Hayes RB, Purdue MP. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev 2010;19:927-31.
35. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am J Epidemiol 2010;171:903-8.